The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

"This study creates a roadmap for this strategy, and future areas of exploration include additional mechanistic studies that ...

Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data ...